Drug repurposing acts to lower the need for early stage clinical trials and can help identify new uses for existing drugs.

People tend to believe that a repurposed therapy can never be truly novel or transformative. Nothing could be further from the truth. One attractive option of Drug Repurposing is to use a scientific approach to identify new uses for existing drugs.

About a third of orphan approvals by the FDA since the program began have been mostly for repurposed mass-market drugs. For example Gleevec, a drug that revolutionized the treatment of chronic myeloid leukemia, now has nine orphan approvals.

BBCR’s team of industry experts can help match treatments to rare genetic conditions and unsolved diseases, then work with a product developer on the best plan to market.

Click to Learn More

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Email

This field is for validation purposes and should be left unchanged.